F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comKopran Limited is a well-known Indian pharmaceutical company engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms. The company has built a strong reputation in both domestic and international markets with its focus on innovation, quality, and compliance with global regulatory standards.
In this article, we’ll explore Kopran Ltd’s share price target from 2025 to 2030, its recent performance, shareholding structure, and long-term investment potential.
| Detail | Value |
|---|---|
| Open | ₹171.50 |
| Previous Close | ₹170.98 |
| Day’s High | ₹173.50 |
| Day’s Low | ₹166.00 |
| 52-Week High | ₹329.00 |
| 52-Week Low | ₹154.06 |
| Market Capitalization | ₹804 Crore |
| Beta (Volatility) | 1.57 |
| VWAP | ₹168.91 |
| Book Value per Share | ₹107.35 |
| Dividend Yield | 1.80% |
| Face Value | ₹10 |
| All-Time High | ₹370.45 |
| All-Time Low | ₹6.00 |
Kopran’s stock has witnessed volatility due to broader market movements and sectoral challenges but remains fundamentally sound with improving financial discipline and steady demand for its key products.
Founded in 1958, Kopran Ltd is part of the Parijat Group and operates in the pharmaceutical manufacturing space. The company’s product portfolio includes cardiovascular, antibiotics, and central nervous system (CNS) drugs. Kopran exports to more than 50 countries and has regulatory approvals from several global authorities such as the USFDA, WHO-GMP, and UKMHRA.
Strong presence in API and formulation exports
Consistent improvement in operational efficiency and margins
Low debt and healthy promoter holding (44.42%)
Investments in R&D for newer molecules
Focused expansion into regulated markets
| Investor Type | Holding (%) |
|---|---|
| Promoters | 44.42% |
| Retail & Others | 54.82% |
| Foreign Institutions | 0.76% |
This structure reflects strong promoter confidence and substantial retail investor participation, a positive sign for long-term stability.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 175 | 190 |
| 2026 | 195 | 215 |
| 2027 | 220 | 245 |
| 2028 | 250 | 280 |
| 2029 | 285 | 320 |
| 2030 | 330 | 375 |
These projections are based on Kopran’s financial performance, sector growth in pharmaceuticals, and market valuation trends.
By 2025, Kopran is expected to maintain steady growth driven by exports and demand for affordable generics.
Why?
Focus on regulated markets
Demand for antibiotic and cardiovascular segments
Strong promoter support
Investment Advice: Long-term investors may consider buying on dips as the company shows resilience in earnings.
In 2026, the company’s export base and improved capacity utilization could enhance profitability.
Why?
New product launches in high-margin therapeutic areas
Operational cost control
Better foreign revenue mix
Investment Advice: Hold or accumulate for long-term compounding returns.
Kopran’s R&D efforts are expected to yield results, improving its product pipeline.
Why?
Expanding API exports to Europe and South America
Higher demand for generic drugs
Strengthened manufacturing infrastructure
Investment Advice: Maintain a medium- to long-term horizon; the stock could outperform the broader pharma index.
By 2028, Kopran’s focus on operational efficiency and global presence might drive significant earnings growth.
Why?
Entry into new regulated markets
Strong domestic performance
Improved net margins
Investment Advice: Good time to accumulate for long-term portfolio diversification.
Kopran could see robust returns as demand for essential and chronic medicines increases.
Why?
Increasing export orders
Better balance sheet strength
Industry-wide expansion in Indian pharma sector
Investment Advice: Ideal for medium-term investors seeking growth and dividend income.
By 2030, Kopran may emerge as a stronger mid-cap player in the Indian pharmaceutical industry.
Why?
Consistent EPS and P/E improvement
Sustainable margins
Strategic investments in new manufacturing units
Investment Advice: Excellent long-term holding for value investors focused on healthcare and pharma sectors.
Yes, Kopran Ltd appears to be a strong long-term bet for investors looking to benefit from India’s pharmaceutical growth story.
Debt-light balance sheet
Steady promoter holding
Expansion in export markets
Consistent dividend payouts
High market volatility (Beta 1.57)
Regulatory risks in export markets
Raw material price fluctuations
Always analyze quarterly performance and consult a financial expert before investing.
Kopran Ltd has shown consistent improvement in operational performance and international reach. With strong fundamentals, healthy promoter confidence, and steady dividend history, the stock could see healthy appreciation over the next five years.
Currently trading around ₹171.50, analysts expect Kopran’s share price to potentially reach ₹375 by 2030, making it an attractive choice for investors focusing on the pharmaceutical and healthcare sector.
Kopran’s long-term growth outlook remains positive, supported by increasing demand for affordable healthcare and India’s growing export opportunities.
What is the next target for Kopran Ltd?
The next short-term target for Kopran Ltd is expected to be between ₹175 and ₹190 in 2025, depending on market conditions.
Is Kopran Ltd a good buy now?
Yes, it’s a good buy for investors with a long-term view, considering its strong fundamentals and dividend yield of 1.8%.
What is the 2025 share price target for Kopran Ltd?
The 2025 share price target is projected between ₹175 and ₹190.
What is Kopran Ltd’s 2030 target?
The 2030 share price target ranges from ₹330 to ₹375.
What is Kopran Ltd’s market capitalization?
As of October 2025, its market capitalization stands at approximately ₹804 Crore.
Is Kopran a debt-free company?
Kopran maintains a manageable debt level and has consistently improved its financial ratios.
What is Kopran’s dividend yield?
Kopran offers a dividend yield of around 1.8%, reflecting consistent shareholder returns.
Who are the major shareholders of Kopran Ltd?
Promoters hold 44.42% of the company’s shares, while retail investors own about 54.82%.
Is Kopran Ltd suitable for long-term investment?
Yes, Kopran Ltd is suitable for investors seeking exposure to the growing Indian pharmaceutical sector.
What is the 52-week high and low of Kopran Ltd?
The 52-week high is ₹329.00, and the 52-week low is ₹154.06.
Disclaimer: This article is for educational and informational purposes only. Please consult a certified financial advisor before making investment decisions.
Register & Login